Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05905250
Other study ID # NCR224269
Secondary ID R21CA261884
Status Recruiting
Phase N/A
First received
Last updated
Start date March 15, 2024
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source George Washington University
Contact Carla J Berg, PhD
Phone 4045585395
Email carlaberg@gwu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We aim to refine and pilot test an 8-week phone- and app-based intervention to promote hope, and thereby mitigate life disruption caused by cancer diagnosis and treatment, among young adults (YAs); our proposal involves (Aim 1) formative research among YA survivors and healthcare providers; and (Aim 2) an randomized controlled trial (RCT) of the intervention vs. attention control among 150 YA cancer survivors. The proposed research is innovative in its use of: 1) a novel intervention target - hope - as a mechanism for addressing goal-disruption and quality of life (QOL) among YA survivors; and 2) novel mHealth components and population-based recruitment strategy (via social media) that are particularly relevant to YA survivors and those with potentially limited access to healthcare. This proposal has potential high impact due to the number of YA cancer survivors for whom the intervention may be relevant, the intervention's potential utility in enhancing hope and QOL among YAs, and its reach/scalability.


Description:

Young adulthood (YA) is a critical time in shaping life trajectories related to educational, financial, and family goals, among others. Unfortunately, cancer diagnosis/treatment and its psychosocial sequelae disrupt this critical period for some YAs. This life goal disturbance is related to poorer psychological outcomes, particularly among YAs; however, goal revision and reprioritization lead to more positive psychological outcomes. Thus, goal negotiation is a critical part of survivorship. Understanding psychosocial determinants of positive psychological and behavioral outcomes is critical for developing effective behavioral interventions. Within the rich positive psychology literature, the construct of hope is one particularly relevant factor for YA cancer survivors; hope has been defined as a positive cognitive state based on a sense of successful goal-directed determination and planning to meet these goals. In the general population and in cancer survivors, hope is related to better quality of life (QOL), mental health, health behaviors, and coping with illness/cancer. Our team pioneered an mHealth intervention (i.e., app-based with phone-based counseling) aimed at increasing hope among YA survivors, thereby re-engaging them in long-term life goals across domains (e.g., vocational, familial) and ultimately increasing QOL. In an 8-week pilot randomized controlled trial (RCT) of 56 YAs recruited from 2 cancer centers, the intervention demonstrated feasibility (95% retention), acceptability (e.g., high satisfaction), and promising trends in changes in hope, QOL, depressive symptoms, and health behaviors (e.g., substance use) in YA survivors. This study builds on our prior work to update the intervention (e.g., its technology), enhance its reach, and increase our ability to examine its effects. Our specific aims are to: 1) conduct formative research examining YA cancer survivor preferences on phone-based counseling with app support to enhance the intervention; and 2) test the feasibility, acceptability, and preliminary efficacy of the intervention vs. attention control (AC) via an 8-week RCT of 150 YA cancer survivors. The proposed research is innovative in its use of a novel intervention target - hope - as a mechanism for addressing goal-disruption and QOL among YA survivors, and its use of novel mHealth components and population-based recruitment strategy (via social media) that are particularly relevant to YA survivors and those with potentially limited access to healthcare.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2024
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 39 Years
Eligibility Inclusion Criteria: - Diagnosis of stage I-IV cancer from age 20-39 - Completion of curative treatment (surgery, chemotherapy and/or radiation) within three years of study enrollment - No significant psychological disabilities - Able to complete forms and understand instructions in English - Smartphone access - Aim 2: Able to commit to 8-week remotely delivered study Exclusion Criteria: - Completion of curative treatment (surgery, chemotherapy and/or radiation) over three years ago or currently in treatment - Significant psychological disabilities

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
an empirically supported protocol, further refined with evidence-based strategies
The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
Health education
Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.

Locations

Country Name City State
United States George Washington University Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
George Washington University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention =>85% retention 2 months (end-of-treatment; EOT)
Primary Retention =>85% retention 6-month (follow-up; FU)
Primary Adherence >75% adherence to intervention components 2 months (end-of-treatment; EOT)
Primary Adherence >75% adherence to intervention components 6-month (follow-up; FU)
Primary Acceptability >75% participants reporting high satisfaction (3 or 4 on scale of 0=not at all to 4=very) 2 months (end-of-treatment; EOT)
Primary Acceptability >75% report yes to "would you recommend this program to your friends who are cancer survivors?" 2 months (end-of-treatment; EOT)
Primary Hope, per Snyder's Hope Scale Higher scores indicate higher hope (scale: 6-48) 6-month (follow-up; FU)
Secondary Hope, per Snyder's Hope Scale Higher scores indicate higher hope (scale: 6-48) 2 months (end-of-treatment; EOT)
Secondary Quality of Life - Patient-Reported Outcome Measurement Information System (PROMIS) Global Health scale Higher scores indicate higher Quality of Life (scale 0-100) (PMCID: PMC2724630) 2 months (end-of-treatment; EOT)
Secondary Quality of Life - Patient-Reported Outcome Measurement Information System (PROMIS) Global Health scale Higher scores indicate higher Quality of Life (scale 0-100) (PMCID: PMC2724630) 6-month (follow-up; FU)
Secondary Quality of Life - Rand Medical Outcome Study 36-Item Short Form Health Survey (SF-36) Higher scores indicate higher Quality of Life (scale: 0-100) (https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html) 2 months (end-of-treatment; EOT)
Secondary Quality of Life - Rand Medical Outcome Study 36-Item Short Form Health Survey (SF-36) Higher scores indicate higher Quality of Life (scale: 0-100) (https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html) 6-month (follow-up; FU)
Secondary Patient Health Questionnaire - 4 item (PHQ-4): Depression and anxiety symptoms Higher score indicates greater depressive and anxiety symptoms (scale: 0-12) 2 months (end-of-treatment; EOT)
Secondary Patient Health Questionnaire - 4 item (PHQ-4): Depression and anxiety symptoms Higher score indicates greater depressive and anxiety symptoms (scale: 0-12) 6-month (follow-up; FU)
Secondary Physical activity Number of days in the past 30 days, engaged in physical activity 2 months (end-of-treatment; EOT) and 6-month (follow-up; FU)
Secondary Alcohol use Number of days in the past 30 days, consumed alcohol 2 months (end-of-treatment; EOT) and 6-month (follow-up; FU)
Secondary Tobacco use Number of days in the past 30 days, used any tobacco product 2 months (end-of-treatment; EOT) and 6-month (follow-up; FU)
Secondary Cannabis use Number of days in the past 30 days, used cannabis 2 months (end-of-treatment; EOT) and 6-month (follow-up; FU)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients